Logo image of CRBU

CARIBOU BIOSCIENCES INC (CRBU) Stock Fundamental Analysis

NASDAQ:CRBU - Nasdaq - US1420381089 - Common Stock - Currency: USD

0.88  +0.08 (+9.75%)

After market: 0.8799 0 (-0.01%)

Fundamental Rating

3

Overall CRBU gets a fundamental rating of 3 out of 10. We evaluated CRBU against 566 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRBU as it has an excellent financial health rating, but there are worries on the profitability. CRBU is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRBU has reported negative net income.
CRBU had a negative operating cash flow in the past year.
In the past 5 years CRBU always reported negative net income.
CRBU had a negative operating cash flow in each of the past 5 years.
CRBU Yearly Net Income VS EBIT VS OCF VS FCFCRBU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -47.59%, CRBU is in line with its industry, outperforming 49.29% of the companies in the same industry.
CRBU has a Return On Equity of -58.95%. This is comparable to the rest of the industry: CRBU outperforms 59.72% of its industry peers.
Industry RankSector Rank
ROA -47.59%
ROE -58.95%
ROIC N/A
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
CRBU Yearly ROA, ROE, ROICCRBU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRBU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRBU Yearly Profit, Operating, Gross MarginsCRBU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

CRBU does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRBU has more shares outstanding than it did 1 year ago.
CRBU has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRBU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRBU Yearly Shares OutstandingCRBU Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
CRBU Yearly Total Debt VS Total AssetsCRBU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

CRBU has an Altman-Z score of -2.26. This is a bad value and indicates that CRBU is not financially healthy and even has some risk of bankruptcy.
CRBU has a Altman-Z score of -2.26. This is comparable to the rest of the industry: CRBU outperforms 53.53% of its industry peers.
There is no outstanding debt for CRBU. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.26
ROIC/WACCN/A
WACC9.96%
CRBU Yearly LT Debt VS Equity VS FCFCRBU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

CRBU has a Current Ratio of 7.16. This indicates that CRBU is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 7.16, CRBU is doing good in the industry, outperforming 69.43% of the companies in the same industry.
A Quick Ratio of 7.16 indicates that CRBU has no problem at all paying its short term obligations.
CRBU's Quick ratio of 7.16 is fine compared to the rest of the industry. CRBU outperforms 69.96% of its industry peers.
Industry RankSector Rank
Current Ratio 7.16
Quick Ratio 7.16
CRBU Yearly Current Assets VS Current LiabilitesCRBU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

CRBU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -13.79%.
Looking at the last year, CRBU shows a very negative growth in Revenue. The Revenue has decreased by -71.01% in the last year.
Measured over the past years, CRBU shows a quite strong growth in Revenue. The Revenue has been growing by 11.54% on average per year.
EPS 1Y (TTM)-13.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-71.01%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%-41.62%

3.2 Future

Based on estimates for the next years, CRBU will show a very strong growth in Earnings Per Share. The EPS will grow by 48.86% on average per year.
Based on estimates for the next years, CRBU will show a very strong growth in Revenue. The Revenue will grow by 169.79% on average per year.
EPS Next Y-4.91%
EPS Next 2Y-3.11%
EPS Next 3Y-4.86%
EPS Next 5Y48.86%
Revenue Next Year-5.98%
Revenue Next 2Y57.35%
Revenue Next 3Y61.97%
Revenue Next 5Y169.79%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRBU Yearly Revenue VS EstimatesCRBU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
CRBU Yearly EPS VS EstimatesCRBU Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 10 15 20 25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRBU. In the last year negative earnings were reported.
Also next year CRBU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRBU Price Earnings VS Forward Price EarningsCRBU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRBU Per share dataCRBU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A cheap valuation may be justified as CRBU's earnings are expected to decrease with -4.86% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.11%
EPS Next 3Y-4.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRBU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARIBOU BIOSCIENCES INC

NASDAQ:CRBU (5/2/2025, 7:48:02 PM)

After market: 0.8799 0 (-0.01%)

0.88

+0.08 (+9.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10 2025-03-10/amc
Earnings (Next)N/A N/A
Inst Owners62.26%
Inst Owner Change1.79%
Ins Owners4.74%
Ins Owner Change21.56%
Market Cap81.84M
Analysts82.67
Price Target13.13 (1392.05%)
Short Float %11.44%
Short Ratio8.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.08%
Min EPS beat(2)9.04%
Max EPS beat(2)17.12%
EPS beat(4)3
Avg EPS beat(4)5.59%
Min EPS beat(4)-13.88%
Max EPS beat(4)17.12%
EPS beat(8)6
Avg EPS beat(8)12.8%
EPS beat(12)9
Avg EPS beat(12)9.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.62%
Min Revenue beat(2)-35.93%
Max Revenue beat(2)-3.31%
Revenue beat(4)1
Avg Revenue beat(4)-11.34%
Min Revenue beat(4)-35.93%
Max Revenue beat(4)11.78%
Revenue beat(8)4
Avg Revenue beat(8)74.46%
Revenue beat(12)6
Avg Revenue beat(12)52.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3%
EPS NQ rev (1m)0.56%
EPS NQ rev (3m)-1.7%
EPS NY rev (1m)-2.26%
EPS NY rev (3m)9.49%
Revenue NQ rev (1m)-12.5%
Revenue NQ rev (3m)-36.36%
Revenue NY rev (1m)-4.86%
Revenue NY rev (3m)-4.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.19
P/FCF N/A
P/OCF N/A
P/B 0.32
P/tB 0.32
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-1.54
FCFYN/A
OCF(TTM)-1.49
OCFYN/A
SpS0.11
BVpS2.72
TBVpS2.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.59%
ROE -58.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.6%
ROA(5y)-41.65%
ROE(3y)-39.9%
ROE(5y)-65.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 124.27%
Cap/Sales 48.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.16
Quick Ratio 7.16
Altman-Z -2.26
F-Score2
WACC9.96%
ROIC/WACCN/A
Cap/Depr(3y)283.95%
Cap/Depr(5y)220.75%
Cap/Sales(3y)43.03%
Cap/Sales(5y)30.75%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-13.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-4.91%
EPS Next 2Y-3.11%
EPS Next 3Y-4.86%
EPS Next 5Y48.86%
Revenue 1Y (TTM)-71.01%
Revenue growth 3Y1.35%
Revenue growth 5Y11.54%
Sales Q2Q%-41.62%
Revenue Next Year-5.98%
Revenue Next 2Y57.35%
Revenue Next 3Y61.97%
Revenue Next 5Y169.79%
EBIT growth 1Y-43.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.51%
EBIT Next 3Y26.59%
EBIT Next 5YN/A
FCF growth 1Y-36.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.14%
OCF growth 3YN/A
OCF growth 5YN/A